The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2023 | Strategies to overcome azacitidine resistance in MDS: combination strategies & mutation analysis
Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, outlines strategies to overcome resistance to azacitidine in patients with myelodysplastic syndromes (MDS), including combination strategies with venetoclax, sabatolimab, and magrolimab, addition of vitamin C, and analyzing mutational signatures to identify patients who are likely to respond better to hypomethylating agents (HMAs). This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
